Objective: There is an increased prevalence of obesity in schizophrenia and bipolar disorder, leading to a disproportionate risk of adverse health conditions. Prospective, long-term weight gain data, however, are scarce.
| INTRODUCTION
Obesity is a major public health problem in the USA, with an estimated 35% of the population considered to be obese (body mass index [BMI] >30 kg/m 2 ). 1 Obesity has significant negative impacts on morbidity and mortality. Obesity increases the risk of adult onset type 2 diabetes, stroke, hyperlipidemia, coronary artery disease, hypertension and cancer. 2 Moreover, obesity is associated with greater impairment in everyday activities, especially physical domains of functioning and disability. 3 In addition, its economic impact on health care expenditures puts a substantial stress on the US health care system. 4 Individuals with schizophrenia (SCZ) and those with bipolar disorder (BP) have an increased prevalence of obesity and related comorbidities compared to the general population, 5 although they are slightly less common and severe in people with BP compared to SCZ. [6] [7] [8] Individuals with both diagnoses are at increased risk of metabolic comorbidities, [9] [10] [11] [12] including dyslipidemia, insulin resistance and hyperglycemia, 13, 14 as well as cardiovascular disease, diabetes, hypertension 15 and metabolic syndrome. 16 The lifespan is 20 years shorter on average for SCZ and 10 years shorter for BP compared to population norms. 11, [17] [18] [19] [20] The reasons for high rates of obesity and attendant medical comorbidities are manifold, extending beyond genetic vulnerability and pharmacological treatments offered. 21, 22 In the context of socioeconomic challenges, persistent mental illness leads to particularly unhealthy lifestyles that include poor diets and little or no physical exercise. [23] [24] [25] [26] Cognitive, symptomatic (i.e., negative and depressive symptoms), medicationinduced extrapyramidal symptoms, and functional capacity limitations add challenges to lifestyle-relevant activities of daily living (ADLs) and instrumental ADLs (e.g., diet, exercise, shopping for food and medical care), creating a vicious cycle that exacerbates health and functional declines 27 with health risk amplified by low rates of medical screening, monitoring, and intervention across health care delivery systems. 28, 29 Most of our knowledge derives from cross-sectional or shortterm studies of clinical samples. In fact, there is little evidence from long-term, prospective studies that sheds light on the extent and timing of weight gain in SCZ and BP. This gap leads to an inability to pinpoint the critical time periods that would lend themselves to prevention efforts. Further, if the diagnostic-specific long-term correlates of weight gain differ for SCZ and BP, it would suggest the need for differential timing and tailoring of prevention and intervention efforts.
In this paper, we present data from a unique 20-year prospective follow-up of a county-wide sample of first-admission patients hospitalized with a psychotic condition in the early 1990s. In-person follow-ups occurred at 6 months, and at 2, 4, 10, and 20 years after their first admission; telephone contacts occurred between these time-points. Self-reported weights were obtained at each follow-up.
Further, the 20-year assessment included systematic measurement of height and weight along with biomarkers for determining metabolic abnormalities.
Our analysis focused on the course of weight gain from the initial follow-up to the 20-year point and the correlates of weight at the 20-year assessment. Weight gain was defined by a standard measure of body mass index (BMI). We compared study participants with SCZ and BP, examining changes over the course of 20 years and associated outcomes. To our knowledge, this is the first study comparing the long-term course of weight gain across different psychotic disorders. In addition to comparison of participants with SCZ and BP, we reference their weight to population normative standards at approximately the same age that these measurements were taken ( Figure 1 ) in order to assess the relative excess in the study sample. 
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| METHODS
| Weight and height measurements
Weight and height were self-reported except for the 20-year assessment, when height and weight were measured. Internal consistency for self-reported height vs measured height was very high and not significantly different in the SCZ and BP groups. Height based on selfreport in the combined sample at year 10 and measured height at year 20 were highly intercorrelated (N=122). The body weight data were collected at 6 months, and 2, 4, 10, and 20 years after the index assessment. The BMI score for each participant was calculated at each assessment (kg/m 2 ). Funding constraints impacted the frequency of assessments. 
| Other measures and biomarkers at the 20-year follow-up
| Statistical analyses
We examined the time course of BMI using a 2 (group)×5 (time) mixedmeasures repeated measures analysis of variance (MMRM ANOVA).
We compared BMI scores at each assessment across the diagnoses using regular t tests. Following those analyses, we characterized all patients as normal weight (BMI ≤24.9), overweight (BMI 25-29.9), and obese (BMI ≥30) at each of the assessments and examined the prevalence of overweight and obesity at each assessment by diagnosis.
We examined the pattern of development of obesity in participants who were overweight early in the course (i.e., at either 6 months or 2 years), also as a function of diagnosis. Participants were divided into those receiving and those not receiving antipsychotic medication at each follow-up, and their subsequent weight gains were compared.
We then examined the correlates of BMI at the 20-year mark in order to identify the factors that were and were not associated with increased weight. Finally, we explored weight gain trajectories in view of changing prescription patterns for antipsychotics: patients enrolled in the study from 1989 to 1992 could initially only have received firstgeneration antipsychotics, whereas those enrolled from 1993 onwards may have been exposed to second-generation antipsychotics.
| RESULTS
Descriptive characteristics of the patients are presented in Table 1 . 
P=.311).
Thus, the two groups had similar increases in weight gain over time which nearly plateaued at the 20-year assessment.
Exploring potential cohort effects of antipsychotics on weight gain due to lack of availability of second-generation antipsychotics at the beginning of the recruitment period did not reveal different weight gain trajectories: the gain was linear when time periods were considered and there were no time periods where, on a years of follow-up corrected basis, there were greater gains. In fact, during years 10−20, when the likelihood of being exposed to weight gain-causing drugs was greatest, there is evidence of a plateauing of weight gain. Interestingly, the use of antipsychotic medication was not associated with longitudinal differences in the course of weight gain, nor was the type/availability of antipsychotics (first vs second generation).
In fact, during years 10−20, when the likelihood of being exposed to the group of weight gain-causing second-generation drugs was great- The general population obesity rate in the USA for adults aged 40-59 years in 2016 was about 35% 35 and in New York State, the 8th leanest state in the USA, 27% in 2014, the most recent data point available. 36 Both the SCZ and BP groups had a higher prevalence of obesity.
Relative to people with normal weight, all-cause mortality of obese persons is higher. 37 We surmise that the increased prevalence of obesity in individuals with SCZ and BP puts them at greater health and mortality risk than the population at large, consistent with previous observations. 8, 9, 11, [19] [20] [21] The trajectory of weight gain is also important. Obese persons with upward weight gain trajectories, even after controlling for demographic and socioeconomic characteristics, smoking status, limitations in activities of daily living, and a wide range of chronic illnesses, have even higher mortality risk than those with static obesity. 38 This suggests that increasing obesity as observed in our sample poses an increasingly substantive mortality threat even 20 years after treatment and later if their weight continues to increase, a fact that clinicians treating patients with persistent mental illness need to keep in mind.
Waist circumference at year 20 was significantly higher in SCZ than in BP. Women with SCZ had higher waist circumferences than men or women with BP. In both BP and SCZ, BMI was more strongly Cholesterol elevations especially are quite simple to treat: statins, for example, are widely available but are still underutilized. 42 Interestingly enough, because weight gain appears to occur later in BP than in SCZ, it is possible that the measured metabolic parameters will also show increasingly detrimental changes, albeit after an even longer observation period. This would allow for a longer window to execute preventative strategies. Moreover, because weight gain continues for 20 years, interventions can be effective in mitigating further weight gain even many years into treatment. Finally, another important conclusion to be drawn from our data is that waist circumference should be measured frequently, especially in women with SCZ.
There are very few truly long-term weight gain data available for both SCZ and BP. Most 'long-term' trials are limited to a 1-year duration if not shorter. [43] [44] [45] [46] [47] Our data represent the most comprehensive weight gain trajectory available to date, having been obtained in a carefully conducted study over 20 years in a well-controlled epidemiological setting. Points of obesity prevention efforts in both SCZ and BP should include early overweight, in that patients who were overweight at 6 months had uniformly high rates of obesity at 20 years, along with increased waist circumference, accounting for much of the metabolic risk subsequently incurred. 48 Moreover, given that weight gain unfolded over 20 years in both groups, with the BP group experiencing later development of obesity relative to the SCZ group, probably due to their lower initial BMI, there may be more time to intervene in BP.
While early weight gain could be targeted with preventative strategies, well-validated preventative strategies remain scarce. Our results call for more investigative effort on how prevention of early weight gain might favorably alter long-term weight trajectories. Long-term interventions aimed at obesity and related cardiovascular risk factors, which have been investigated more comprehensively, should include implementation strategies that effectively translate these modestly efficacious interventions into real-world settings, 49, 50 for the mitigation of further weight gain and weight loss along the 20-year weight gain trajectory.
| LIMITATIONS
This was a single-site study. We did not determine if the rates of weight gain were different from what would be expected across the early adult life course in healthy comparators. The ability to analyze effects of antipsychotic medications was somewhat limited in that cumulative exposure was not assessed. There may be survivorship effects in our data. We also combined schizophrenia and schizoaffective disorder into one category (SCZ). We cannot exclude the possibility that schizoaffective disorder patients had a different weight gain propensity, as some prior literature has suggested.
However, we believe that the weight gain trajectory may not have been too dissimilar from that in the BP and SCZ groups, both of whom gained weight in parallel, but with a somewhat different time course. There also were no data presented on whether there were treatments for hyperlipidemia or diabetes that might have altered the biomarkers.
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